方法：将接受玻璃体腔注射康柏西普治疗的30例患者随机分为两组：前房穿刺组(A组)和未行前房穿刺组(B组)，A组在玻璃体腔内注射康柏西普同时行前房穿刺，B组仅玻璃体腔内注射康柏西普。应用AccuPen手持式回弹眼压计于治疗前及治疗后2、30、60min，1d，1wk测量眼压，并进行比较。

结果：与术前眼压比较，A组术后各时间点眼压变化无统计学差异(P>0.05)； B组术后2min眼压骤升至42.4±9.3mmHg，与A组同时间点眼压比较，差异有统计学意义(P<0.05)； 30min时降至17.4±5.0mmHg，与A组同时间点眼压比较，差异无统计学意义(P>0.05)。

结论：玻璃体腔注射康柏西普术中行前房穿刺能够有效控制注射后的早期眼压升高。

METHODS: A prospective,randomized-controlled clinical trial was conducted on 30 eyes of 30 patients underwent intravitreal injection of Conbercept. The patients were randomly divided into Group A(15 patients with 22 treatments)and Group B(15 patients with 23 treatments)according to whether to applying anterior chamber paracentesis. IOP was measured before injection and 2, 30, 60min, 1d and 1wk after the injection with AccuPen tonometer.

RESULTS: Compared with preoperative intraocular pressure, there was no significant change in IOP of Group A(applying anterior chamber paracentesis)at any time we observed(P>0.05); while the IOP of Group B significantly increased at 2min after injection(42.4±9.3mmHg)with significant difference compared to Group A(P<0.05), and then the IOP dropped to normal(17.4±5.0mmHg)within 30min without significant difference compared to Group A(P>0.05).

CONCLUSION: Intraoperative anterior chamber paracentesis during intravitreal Conbercept can effectively control the early stage intraocular pressure raise after the injection.